Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has been assigned an average rating of “Buy” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $12.38.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th.

Institutional Trading of Corvus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtus ETF Advisers LLC purchased a new position in shares of Corvus Pharmaceuticals in the 4th quarter worth about $47,000. Nwam LLC bought a new stake in Corvus Pharmaceuticals in the third quarter worth about $53,000. PKS Advisory Services LLC bought a new stake in Corvus Pharmaceuticals in the fourth quarter worth about $56,000. Alpine Global Management LLC purchased a new position in Corvus Pharmaceuticals in the fourth quarter valued at about $62,000. Finally, ExodusPoint Capital Management LP bought a new position in shares of Corvus Pharmaceuticals during the 4th quarter valued at approximately $72,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $4.25 on Tuesday. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The stock has a market capitalization of $273.09 million, a price-to-earnings ratio of -4.57 and a beta of 0.91. The company’s 50 day simple moving average is $4.72 and its 200 day simple moving average is $6.10.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.